Dr. Reddy's Laboratories Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Dr. Reddy's Laboratories yıllık ortalama 27.1% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.4% annual. Gelirler growing yılda ortalama 12.1% oranında artmaktadır. Dr. Reddy's Laboratories'in özkaynak karlılığı 17.5% ve net marjı 17.8%'dir.
Anahtar bilgiler
27.1%
Kazanç büyüme oranı
27.0%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 17.5% |
| Gelir büyüme oranı | 12.1% |
| Özkaynak getirisi | 17.5% |
| Net Marj | 17.8% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Are Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Investors Paying Above The Intrinsic Value?
Nov 23
Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Nov 08Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price
Nov 01Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Oct 14If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
May 10With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
May 06There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?
Jan 19Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E
Jan 01Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet
Oct 21If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Oct 03Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt
Jul 14Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
Jun 24Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year
Jun 10Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
May 27Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00
May 13Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Apr 11If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Mar 06These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well
Jan 10If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Dec 05Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Dr. Reddy's Laboratories nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 299,867 | 53,332 | 86,402 | 25,906 |
| 30 Jun 24 | 288,507 | 55,579 | 82,190 | 24,082 |
| 31 Mar 24 | 279,164 | 55,684 | 77,201 | 22,873 |
| 31 Dec 23 | 271,302 | 52,206 | 74,717 | 21,362 |
| 30 Sep 23 | 266,854 | 50,888 | 72,470 | 20,618 |
| 30 Jun 23 | 261,109 | 47,216 | 70,235 | 20,040 |
| 31 Mar 23 | 245,879 | 45,067 | 68,026 | 19,381 |
| 31 Dec 22 | 237,279 | 36,350 | 65,708 | 18,341 |
| 30 Sep 22 | 222,776 | 30,944 | 63,138 | 17,679 |
| 30 Jun 22 | 217,351 | 29,736 | 62,529 | 17,273 |
| 31 Mar 22 | 214,391 | 23,568 | 62,081 | 17,482 |
| 31 Dec 21 | 207,307 | 26,317 | 60,717 | 17,250 |
| 30 Sep 21 | 203,406 | 19,450 | 59,693 | 17,199 |
| 30 Jun 21 | 194,741 | 17,153 | 56,849 | 17,095 |
| 31 Mar 21 | 189,722 | 17,238 | 54,650 | 16,541 |
| 31 Dec 20 | 186,756 | 21,256 | 52,457 | 16,637 |
| 30 Sep 20 | 181,298 | 15,361 | 50,740 | 16,478 |
| 30 Jun 20 | 180,340 | 18,663 | 50,850 | 15,781 |
| 31 Mar 20 | 174,600 | 19,498 | 50,129 | 15,410 |
| 31 Dec 19 | 170,448 | 16,200 | 50,246 | 14,882 |
| 30 Sep 19 | 165,110 | 26,749 | 49,484 | 14,601 |
| 30 Jun 19 | 155,079 | 20,862 | 48,639 | 15,059 |
| 31 Mar 19 | 153,851 | 18,795 | 48,680 | 15,607 |
| 31 Dec 18 | 149,034 | 17,473 | 48,400 | 16,293 |
| 30 Sep 18 | 148,594 | 15,965 | 48,540 | 17,292 |
| 30 Jun 18 | 145,903 | 13,776 | 47,200 | 17,347 |
| 31 Mar 18 | 141,855 | 9,806 | 46,857 | 18,265 |
| 31 Dec 17 | 141,827 | 9,909 | 45,370 | 18,458 |
| 30 Sep 17 | 140,588 | 11,266 | 44,663 | 18,747 |
| 30 Jun 17 | 140,907 | 11,367 | 45,405 | 19,786 |
| 31 Mar 17 | 139,870 | 12,039 | 46,300 | 19,513 |
| 31 Dec 16 | 141,269 | 9,660 | 46,961 | 19,718 |
| 30 Sep 16 | 144,127 | 10,751 | 47,659 | 18,857 |
| 30 Jun 16 | 148,410 | 15,019 | 46,943 | 18,116 |
| 31 Mar 16 | 153,866 | 20,013 | 45,641 | 17,701 |
| 31 Dec 15 | 155,850 | 24,456 | 44,152 | 18,100 |
| 30 Sep 15 | 154,602 | 24,409 | 43,264 | 18,321 |
| 30 Jun 15 | 150,592 | 22,932 | 42,879 | 17,961 |
| 31 Mar 15 | 147,360 | 22,179 | 42,076 | 17,329 |
| 31 Dec 14 | 143,474 | 21,806 | 42,810 | 16,289 |
| 30 Sep 14 | 140,380 | 22,247 | 42,102 | 14,952 |
| 30 Jun 14 | 138,076 | 23,409 | 41,165 | 13,847 |
| 31 Mar 14 | 132,170 | 21,515 | 38,783 | 12,402 |
| 31 Dec 13 | 130,043 | 22,409 | 37,695 | 10,852 |
Kaliteli Kazançlar: DRREDDY yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: DRREDDY 'nin mevcut net kar marjları (17.8%) geçen yılın (19.1%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: DRREDDY şirketinin kazançları son 5 yılda yılda 27.1% oranında önemli ölçüde arttı.
Büyüme Hızlandırma: DRREDDY 'un son bir yıldaki kazanç büyümesi ( 4.8% ) 5 yıllık ortalamasının ( 27.1% /yıl) altındadır.
Kazançlar vs. Sektör: DRREDDY geçen yılki kazanç büyümesi ( 4.8% ) Pharmaceuticals sektörünün 20% performansını geride bırakmadı.
Özkaynak Getirisi
Yüksek ROE: DRREDDY 'nin Özsermaye Getirisi ( 17.5% ) düşük olarak değerlendiriliyor.